Physician profile
Malorie Irwin
NPI 1477925527
$13,651.96
in general payments reported to CMS, 2019-2025
73 companies · $3,555 in 2025
The $3,555 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $764 · 2022: $3,244 · 2023: $3,206 · 2024: $2,884 · 2025: $3,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,989 · Education: $356 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,989.21 |
| Education | $356.00 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,407.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,315.78 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Exelixis INC. | $1,188.12 | 2023 | Cabometyx |
| Daiichi Sankyo INC. | $1,042.26 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $719.39 | 2021-2025 | |
| Janssen Biotech, INC. | $658.69 | 2021-2025 | Talvey, Rybrevant, Tecvayli |
| Celgene Corporation | $604.38 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $484.73 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Incyte Corporation | $369.79 | 2021-2025 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $337.93 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Genzyme Corporation | $328.78 | 2021-2025 | |
| Genentech USA, INC. | $307.22 | 2021-2025 | Polivy, Tecentriq, Columvi |
| Amgen INC. | $296.77 | 2021-2023 | Blincyto, Kyprolis, Lumakras |
| Abbvie INC. | $267.95 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.56 | 2021-2024 | Ninlaro, Alunbrig, Cuvitru |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malorie Irwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.